Investigators report that the glutaminase inhibitor CB-839 preferentially inhibited xenograft growth of PIK3CA-mutant, but not wild-type, colorectal cancer. Moreover, the combination of CB-839 and 5-fluorouracil induces PIK3CA-mutant tumor regression in xenograft models.
1254621 JL75HLNL items 1 apa default asc 1
The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
[The Leukemia & Lymphoma Society (PRNewswire,LLC)]
Celularity announced that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells for the treatment of adults with COVID-19 as part of a national clinical trial.
INmune Bio, Inc. announced that the FDA has accepted the company’s Investigational New Drug application to initiate a Phase II clinical trial evaluating Quellor™, a selective soluble tumor necrosis factor inhibitor, for the treatment of immune mediated complications in COVID-19 patients.
[INmune Bio, Inc. (BusinessWire, Inc.)]
Madrigal Pharmaceuticals, Inc. announced that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments.
[Madrigal Pharmaceuticals, Inc. (GlobeNewswire)]
UroGen Pharma Ltd. has announced that the Phase II APOLLO clinical trial of a RTGel hydrogel formulation in combination with BOTOX® (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder and urinary incontinence did not meet the primary endpoint
[UroGen Pharma Ltd. (Businesswire, Inc.)]
Investigators attempt to understand the classical and non-classical signaling role of progesterone in breast cancers because both nuclear and membrane receptors could become viable therapeutic options for breast cancer patients.
Researchers investigated four candidate solutions for transporting human keratinocytes.
6807162 NMSXYY4X items 1 apa default asc 1
Natera, Inc. announced a collaborative agreement with Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib for the treatment of ER-positive breast cancer, the first circulating tumor DNA based study of a CDK4/6 inhibitor in ER-positive early stage breast cancer.
Investigators tested human erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 directed CAR T cells for their capacity to target and kill human paediatric osteosarcoma and Ewing sarcoma tumour cells using in vitro and in vivo assays.
[Cancer Gene Therapy]
Pluristem Therapeutics, Inc. announced FDA has cleared the Company’s Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19 outside of the Company’s ongoing Phase II COVID-19 study in the US.
[Pluristem Therapeutics, Inc.]